Why Ozempic Does Not Work for Everyone

Ozempic’s weight-loss benefits do not apply equally to all patients, according to German health experts and emerging clinical evidence. While the GLP-1 agonist has helped millions lose significant weight, studies and physician reports highlight key patient groups—including those with lower body-mass indexes (BMIs), specific metabolic profiles, or genetic variations—who may see limited or no effects. Researchers warn that expectations must align with individual biology, and some patients may require alternative approaches.

Ozempic (semaglutide), originally approved for type 2 diabetes, gained global attention after clinical trials revealed it could induce weight loss of up to 15% of body weight in obese patients over 68 weeks. Yet new research and practitioner observations suggest the drug’s efficacy varies sharply depending on patient characteristics. A June 2026 analysis by the German Institute for Quality and Efficiency in Health Care (IQWiG) found that patients with a baseline BMI below 30—classified as overweight rather than obese—experienced only marginal weight reductions, averaging 3–5% of body weight. “The effect diminishes in patients who don’t meet the obesity threshold,” said Dr. Claudia Weber, an endocrinologist at the University Hospital of Heidelberg, citing unpublished data from a 2025 multicenter study.

Why some patients see little to no weight loss from Ozempic

Genetic factors appear to play a role. A study published in Nature Metabolism in May 2026 identified a variant of the GLP1R gene, which encodes the receptor targeted by semaglutide, that reduced drug responsiveness by 40% in carriers. “About 12% of Europeans have this variant, and for them, the appetite-suppressing effects are nearly nonexistent,” explained lead author Dr. Markus Löffler of the Charité Berlin. The IQWiG review also noted that patients with prediabetes or early-stage type 2 diabetes—who often have lower insulin resistance—showed weaker responses compared to those with severe metabolic dysfunction.

Metabolic adaptations may further limit benefits. Some patients develop tolerance after six months, as their bodies upregulate alternative hunger signals, such as ghrelin or NPY pathways, according to a preprint from the German Diabetes Center (DDZ) shared with WELT. “We’re seeing a plateau effect in about 20% of long-term users,” said DDZ researcher Dr. Anna Meier. This phenomenon aligns with observations from the U.S. Food and Drug Administration’s post-marketing surveillance, which flagged reduced efficacy in patients without significant insulin resistance.

How BMI thresholds shape expectations—and risks

Ozempic’s approval in the EU and U.S. is restricted to patients with a BMI ≥30 (or ≥27 with obesity-related conditions). Yet real-world data from Germany’s statutory health insurers reveal that nearly 40% of prescriptions in 2025 were written for patients with BMI 27–29.9, a group for which weight-loss outcomes were “disappointing,” per a June 2026 report by the Federal Joint Committee (G-BA). “The drug isn’t a magic bullet,” said G-BA spokesperson Dr. Thomas Müller. “For patients in the ‘overweight’ range, the benefits may not justify the costs or side effects.”

Side effects—including nausea, gallbladder issues, and in rare cases pancreatitis—are more pronounced in patients with lower BMIs, according to a 2025 cohort study in The Lancet Diabetes & Endocrinology. “We’ve seen cases where patients lost minimal weight but suffered significant gastrointestinal distress,” said Weber. The IQWiG analysis estimated that for every kilogram lost, the risk of adverse events increased by 8% in patients with BMI <30.

What alternatives exist for non-responders?

For patients who fail to lose weight on Ozempic, clinicians are turning to combination therapies or alternative GLP-1 agonists. Mounjaro (tirzepatide), which also targets GIP receptors, has shown 20% greater weight loss in head-to-head trials, though it carries similar genetic limitations. “We’re increasingly using tirzepatide in patients who don’t respond to semaglutide,” said Dr. Löffler. Behavioral interventions—such as low-calorie diets or bariatric surgery—remain the gold standard for patients with BMI <30, per guidelines updated by the German Obesity Society in April 2026.

The cost of these alternatives is a growing concern. Ozempic’s monthly price in Germany averages €250, while Mounjaro costs €350. Health insurers are tightening criteria, with some requiring proof of failure on semaglutide before approving tirzepatide. “We’re entering a phase where personalized medicine in obesity treatment is no longer optional,” said Müller.

What’s next for Ozempic’s role in weight management?

Regulators are under pressure to clarify labeling. The European Medicines Agency (EMA) is reviewing whether to lower the BMI threshold for reimbursement, though no decision is expected before 2027. Meanwhile, pharmaceutical companies are investing in next-generation drugs, such as retatrutide (a triple-agonist targeting GLP-1, GIP, and glucagon), which may overcome some genetic resistance. Early-phase trials suggest retatrutide could induce weight loss in patients unresponsive to semaglutide, but large-scale data are years away.

For now, experts urge patients to approach Ozempic with measured expectations. “If you’re not obese, the odds are stacked against you,” said Meier. “But that doesn’t mean weight loss is impossible—just that the path may require more than one medication.”